Holen Sie sich die Stockscreener-App
4.65
6.41%
0.28
Handel nachbörslich:
4.56
-0.09
-1.94%
Taysha Gene Therapies Inc Aktie (TSHA) Neueste Nachrichten
Taysha Gene Therapies (TSHA) Making Progress on Crucial Rett Syndrome Treatment - Yahoo Finance
Taysha Gene Therapies (NASDAQ:TSHA) Shares Up 6.9% on Analyst Upgrade - marketbeat.com
Taysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $17.00 - marketbeat.com
CCORF Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $17 - Moomoo
Canaccord raises Taysha Gene Therapies price target on trial progress - Investing.com
Capricorn Fund Managers Ltd Makes New Investment in Taysha Gene Therapies, Inc. $TSHA - marketbeat.com
5 Best Multibagger Penny Stocks to Invest In - Insider Monkey
Citizens Maintains Taysha Gene Therapies (TSHA) Market Outperform Recommendation - MSN
Taysha Gene Therapies upgraded at Goldman Sachs on advancing Rett syndrome asset - MSN
Aug Patterns: Is Taysha Gene Therapies Inc undervalued by DCF analysis2026 Institutional & Reliable Price Breakout Alerts - baoquankhu1.vn
TSHA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
SG Americas Securities LLC Acquires 748,525 Shares of Taysha Gene Therapies, Inc. $TSHA - marketbeat.com
Hennion & Walsh Asset Management Inc. Invests $1.70 Million in Taysha Gene Therapies, Inc. $TSHA - marketbeat.com
Should you avoid Taysha Gene Therapies Inc stock right nowProfit Target & Weekly Top Gainers Trade List - baoquankhu1.vn
Taysha outlines 2026 BLA submission path for TSHA-102 as pivotal trial enrollment advances - MSN
Buybacks Report: Is Taysha Gene Therapies Inc undervalued by DCF analysisQuarterly Investment Review & AI Driven Stock Movement Reports - baoquankhu1.vn
Aug Catalysts: Will Taysha Gene Therapies Inc benefit from AI trendsJobs Report & Verified Momentum Stock Alerts - baoquankhu1.vn
Taysha Gene Therapies (NASDAQ:TSHA) Stock Rating Upgraded by Truist Financial - marketbeat.com
Panic Selling: Whats the fair value of Taysha Gene Therapies Inc stockCEO Change & Technical Entry and Exit Alerts - baoquankhu1.vn
Levels Update: Whats the fair value of Taysha Gene Therapies Inc stock2026 Winners & Losers & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 8.5%Should You Buy? - MarketBeat
Cantor Fitzgerald reiterates Overweight on Taysha Gene Therapies stock By Investing.com - Investing.com Canada
Cantor Fitzgerald Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $19 - Moomoo
Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 6.9%Time to Sell? - MarketBeat
Taysha Gene Therapies FY 2025 earnings preview - MSN
How FDA Breakthrough Status For TSHA-102 At Taysha Gene Therapies (TSHA) Has Changed Its Investment Story - Yahoo Finance
BMO Capital Sticks to Their Buy Rating for Taysha Gene Therapies (TSHA) - The Globe and Mail
Taysha Gene Therapies Receives 'Moderate Buy' Rating from Analysts - National Today
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Taysha Gene Therapies (NASDAQ:TSHA) Stock Rating Upgraded by Wall Street Zen - marketbeat.com
Chardan Capital Maintains Taysha Gene Therapies (TSHA) Buy Recommendation - MSN
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2025 Earnings Call Transcript - Insider Monkey
Taysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $12.00 at Needham & Company LLC - MarketBeat
Decoding Taysha Gene Therapies Inc (TSHA): A Strategic SWOT Insi - GuruFocus
Taysha Gene Therapies Q4 Loss Of US$27.9m Tests Bullish TSHA 102 Narrative - simplywall.st
Taysha Gene Therapies Signals Momentum in Earnings Call - TipRanks
Taysha Gene Therapies (TSHA) Advances Rett Syndrome Treatment - GuruFocus
Jefferies raises Taysha Gene Therapies price target on trial progress By Investing.com - Investing.com Canada
Key facts: Taysha $109M loss; Q4 rev +171%; $320M cash; TSHA-102 safe, Q2'26 - TradingView
TSHA: Analyst Chardan Capital Maintains Buy Rating with $12 PT | - GuruFocus
Chardan Capital Reaffirms "Buy" Rating for Taysha Gene Therapies (NASDAQ:TSHA) - MarketBeat
Raymond James reiterates Strong Buy on Taysha Gene Therapies stock By Investing.com - Investing.com Australia
Taysha Gene Therapies Inc (TSHA) Q4 2025 Earnings Call Highlight - GuruFocus
Taysha Gene Therapies Q4 2025 Earnings Call Transcript - MarketBeat
Taysha Gene Therapies, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Taysha Gene Therapies’ Q4 Earnings Call: FDA Timeline, European Strategy Claims Don’t Match Prior Statements - Bitget
Taysha (TSHA) Reports Strong Q4 Revenue and Promising Progress i - GuruFocus
Taysha Gene Therapies Q4 Earnings Call Highlights - MarketBeat
Taysha Gene Therapies 2026 Conference Call: TSHA-102 Development & Regulatory PlansNews and Statistics - IndexBox
Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update - Investing News Network
TSHA: TSHA-102 advanced toward registration with strong trial data, FDA alignment, and solid cash runway - TradingView
Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up After Better-Than-Expected Earnings - MarketBeat
Taysha Gene Therapies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Taysha (TSHA) Fourth Quarter 2025 Earnings Conference Call Transcript - Bitget
Taysha (TSHA) Q4 2025 Earnings Call Transcript - AOL.com
Earnings call transcript: Taysha Gene Therapies Q4 2025 sees widened loss - Investing.com Canada
Earnings call transcript: Taysha Gene Therapies Q4 2025 sees widened loss By Investing.com - Investing.com South Africa
Taysha Gene Therapies (NASDAQ:TSHA) Releases Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):